Hematologic outcomes and exploratory pharmacogenetic associations in patients receiving docetaxel-containing chemotherapy: a retrospective study

Background Hematologic abnormalities are a clinical concern during docetaxel-containing chemotherapy. This study aimed to characterize paired hematologic changes and study-defined cytopenia and explore associations with candidate genetic variants. Method This retrospective study included 67 adults with solid tumors receiving docetaxel (70 mg/m 2 ) in combination regimens between June 2021 and March 2022. Measurements before and 3–10 days after an index cycle were compared using paired tests. Associations between 16 variants and five post-treatment hematologic outcomes were assessed using linear regression adjusted for baseline measurements and clinical covariates. Benjamini–Hochberg (BH) correction was applied separately to additive and alternative inheritance models. Results Mean white blood cell (WBC) count changed by −1.88 × 10 9 /L (95% confidence interval [CI], −2.53 to −1.23), and absolute neutrophil count (ANC) by −1.16 × 10 9 /L (95% CI, −1.77 to −0.55; both unadjusted P < 0.001). Study-defined grade 3–4 leukopenia and neutropenia were observed in 18 (26.9%) and 19 (28.4%) patients, respectively. Four of 80 primary additive tests had unadjusted P < 0.05, but none met BH q < 0.05 (minimum q = 0.666). For cytochrome P450 family one subfamily B member 1 (CYP1B1) rs1056836, adjusted post-treatment differences comparing GC/GG with CC were 1.21 × 10 9 /L for WBC (95% CI, 0.09 to 2.34; P = 0.036) and 1.08 × 10 9 /L for ANC (95% CI, 0.13 to 2.03; P = 0.027); both q values were 0.882. Conclusion Post-treatment WBC and ANC were lower than pretreatment values. Neither the primary additive analyses nor the evaluated alternative CYP1B1 models identified associations meeting the multiplicity-adjusted significance threshold.

Authors

Institutions

Publication Details

Journal
Frontiers in Genetics
Published
2026-11-16
DOI
https://doi.org/10.3389/fgene.2026.1996630
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hematologic outcomes and exploratory pharmacogenetic associations in patients receiving docetaxel-containing chemotherapy: a retrospective study

Yun-Chang Yao, Rupu He, Yao Wang, Dan Wang et al.
Frontiers in Genetics
Pharmacogenetics and Drug Metabolism
article

Hematologic outcomes and exploratory pharmacogenetic associations in patients receiving docetaxel-containing chemotherapy: a retrospective study

Yun-Chang Yao, Rupu He, Yao Wang, Dan Wang, Li-Shan Lu, Xue-Mei Tian, Qing Yang, Pei-Tao Xie
article en

Abstract

Background Hematologic abnormalities are a clinical concern during docetaxel-containing chemotherapy. This study aimed to characterize paired hematologic changes and study-defined cytopenia and explore associations with candidate genetic variants. Method This retrospective study included 67 adults with solid tumors receiving docetaxel (70 mg/m 2 ) in combination regimens between June 2021 and March 2022. Measurements before and 3–10 days after an index cycle were compared using paired tests. Associations between 16 variants and five post-treatment hematologic outcomes were assessed using linear regression adjusted for baseline measurements and clinical covariates. Benjamini–Hochberg (BH) correction was applied separately to additive and alternative inheritance models. Results Mean white blood cell (WBC) count changed by −1.88 × 10 9 /L (95% confidence interval [CI], −2.53 to −1.23), and absolute neutrophil count (ANC) by −1.16 × 10 9 /L (95% CI, −1.77 to −0.55; both unadjusted P < 0.001). Study-defined grade 3–4 leukopenia and neutropenia were observed in 18 (26.9%) and 19 (28.4%) patients, respectively. Four of 80 primary additive tests had unadjusted P < 0.05, but none met BH q < 0.05 (minimum q = 0.666). For cytochrome P450 family one subfamily B member 1 (CYP1B1) rs1056836, adjusted post-treatment differences comparing GC/GG with CC were 1.21 × 10 9 /L for WBC (95% CI, 0.09 to 2.34; P = 0.036) and 1.08 × 10 9 /L for ANC (95% CI, 0.13 to 2.03; P = 0.027); both q values were 0.882. Conclusion Post-treatment WBC and ANC were lower than pretreatment values. Neither the primary additive analyses nor the evaluated alternative CYP1B1 models identified associations meeting the multiplicity-adjusted significance threshold.

Frontiers in GeneticsVol. 17
Inner Mongolia Medical University (CN)
Natural Science Foundation of Inner Mongolia
Good health and well-being
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon